EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review

Silvia R Vitale iD, Melissa Drago, Federica Martorana iD, Chiara Conti iD, Michele Massimino iD, Stefania Stella, Cristina Tomarchio iD, Paolo Vigneri, Livia Manzella

Pharmaceutics · 29.07.2026 · 18 (8) · 928

DOI: 10.3390/pharmaceutics18080928 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.07.2026. Verfasst von Silvia R Vitale und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences (United States).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenetics has transformed oncology by enabling personalized, effective and safer use of anticancer therapies. Among clinically relevant pharmacogenetic biomarkers, polymorphisms in the UGT1A1 gene influence the metabolism of irinotecan and other SN-38-based agents, increasing the risk of treatment-related toxicities. Beyond SN-38-based therapies, UGT1A1 contributes to the metabolism of endogenous compounds and several drugs, and its activity may be affected by concomitant inhibitors or inducers, highlighting its broader clinical relevance. Although substantial evidence supports the association between UGT1A1 genotype and drug safety, implementation of genotype-guided treatment remains inconsistent. This narrative review summarizes the biological basis and clinical relevance of UGT1A1 polymorphisms in patients receiving SN-38-based therapies. Original studies, systematic reviews, meta-analyses, and international and regional pharmacogenetic guidelines were evaluated regarding genotype-guided dosing, clinical outcomes, implementation strategies, and barriers to routine testing. Reduced-function UGT1A1 variants are associated with increased risk of irinotecan-induced neutropenia and diarrhea, particularly at higher doses. However, recommendations from scientific societies differ regarding testing indications, dose adjustment strategies, and patient selection. Uncertainties remain concerning the clinical implications of UGT1A1 variability for newer antibody–drug conjugates carrying an SN-38 payload. Practical barriers, including inconsistent guideline recommendations, limited access to testing, reimbursement issues, and heterogeneous clinical workflows, continue to restrict implementation. UGT1A1 genotyping represents a valuable tool for improving the safety of selected anticancer therapies, yet its incorporation into clinical practice remains incomplete. As precision oncology evolves, pharmacogenetic testing may optimize treatment selection, reduce toxicity, and improve outcomes. Further harmonization of international recommendations, high-quality prospective studies, and wider access to pharmacogenetic testing are needed to support routine implementation.

Schlagwörter

Stichwörter der Autor:innen

UGT1A1 polymorphismsadverse eventsanticancer therapydrug–drug interactionspharmacogenetics

Autor:innen und Institutionen

  • Center of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.
  • Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
  • Humanitas Istituto Clinico Catanese, Misterbianco, 95125 Catania, Italy.
  • Department of General Surgery and Medical-Surgical Sciences, University of Catania, 95123 Catania, Italy.

ORCID-Profile: Silvia R Vitale, Federica Martorana, Chiara Conti, Michele Massimino, Cristina Tomarchio

Förderung

  • Gilead Sciences (United States)

Zitieren

APA

Vitale, S. R., Drago, M., Martorana, F., Conti, C., Massimino, M., Stella, S., Tomarchio, C., Vigneri, P., & Manzella, L. (2026). Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review. Pharmaceutics, 18(8), 928. https://doi.org/10.3390/pharmaceutics18080928

Vancouver

Vitale SR, Drago M, Martorana F, Conti C, Massimino M, Stella S, et al. Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review. Pharmaceutics. 2026;18(8):928. doi:10.3390/pharmaceutics18080928

BibTeX
@article{Vitale2026,
  author = {Vitale, Silvia R and Drago, Melissa and Martorana, Federica and Conti, Chiara and Massimino, Michele and Stella, Stefania and Tomarchio, Cristina and Vigneri, Paolo and Manzella, Livia},
  title = {Clinical Implications of UGT1A1 Polymorphisms in Anticancer Therapy: An Updated Review},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {928},
  doi = {10.3390/pharmaceutics18080928}
}
Kostenlos starten →